Despite the rapid scientific advances with new targets, modalities, and biomarkers, the return on invested capital (ROIC) in novel therapeutics remains low. The problem stems from the large investment needed, high risks of failure, and long timelines until revenues can be realized. This situation is becoming increasingly worse due to expensive trials in more difficult-to-recruit populations, and with new targets and modalities increasing the competition and market uncertainty.
In the first of three articles looking at clinical development strategies, CRA’s Dr. Nick Davies, presents a unified approach to optimizing return on investment in R&D, focusing on the interplay between clinical and commercial factors in the development of novel therapeutics.
In the next article, this approach is applied to a simulated example of an oncology asset entering Phase 3 that is in a head-to-head race with pipeline competitor(s).
Click here to read more the analytics for clinical development strategy.
